Federal contract award
HHSO10033001T
IGF::OT::IGF FOR OTHER FUNCTIONS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 325414 — Biological Product (except Diagnostic) Manufacturing |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | HHSO100201100009I |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $590.3K |
| Current contract value | $590.3K |
| Potential contract value / ceiling | $590.3K |
| Start date | Nov 29, 2013 |
| Current end date | Jun 24, 2024 |
| Potential end date | Jun 24, 2024 |
| Latest award activity | Jun 26, 2024 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 4 of 4 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jun 26, 2024 | P00003 | $0 | "A PILOT ?PROOF OF CONCEPT? (POC) NON-CLINICAL STUDY USING MULTISTEM? AS A MITIGATOR IN C57BL6J MICE TO DETERMINE THE POTENTIAL EFFICACY AND SAFETY AS A MEDICAL COUNTERMEASURE (MCM) PRODUCT THAT PROVIDES MITIGATION OR RECOVERY OF THE HEMATOPOIET |
| Sep 24, 2020 | P00002 | $-456.4K | "A PILOT ?PROOF OF CONCEPT? (POC) NON-CLINICAL STUDY USING MULTISTEM? AS A MITIGATOR IN C57BL6J MICE TO DETERMINE THE POTENTIAL EFFICACY AND SAFETY AS A MEDICAL COUNTERMEASURE (MCM) PRODUCT THAT PROVIDES MITIGATION OR RECOVERY OF THE HEMATOPOIET |
| Sep 15, 2014 | 1 | $332.2K | IGF::OT::IGF FOR OTHER FUNCTIONS |
| Nov 6, 2013 | 0 | $714.5K | IGF::OT::IGF FOR OTHER FUNCTIONS |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.